Genomic Vision’s Cutting-Edge TeloSizer® Application to be Used in Cancer Research

Genomic Vision and CNRS launch a core oncology program with the Cancer Research Center of Marseille to develop companion tests based on TeloSizer®
BAGNEUX, France–(BUSINESS WIRE)–Regulatory News:

Genomic Vision (Paris:GV) (FR0011799907 – GV, the “Company”), a Euronext-listed biotechnology company that develops tools and services for the highly accurate characterization of DNA sequences, is pleased to announce a collaboration with the Centre National de la Recherche Scientifique (CNRS), the French state research organization, to launch a four-year core scientific program with the Cancer Research Center of Marseille (CRCM) for the development of companion diagnostic tests using Genomic Vision’s TeloSizer® application.

Telomeres are repetitive nucleotide sequences that form the ends of linear chromosomes. TeloSizer® allows for high precision measurement of telomere length and distribution to uncover links between telomere length and the onset and severity of diseases such as cancer and age-associated diseases.

Learn more about TeloSizer® by visualizing the video: https://info.genomicvision.com/TeloSizer

“Genomic Vision continues to apply its innovative technologies for the benefit of patients and this collaboration with CNRS is an important milestone. We are pioneering the use of telomere length as a disease biomarker and this will contribute to cancer research.” said Thierry Huet, Ph.D., Research and Development Director of Genomic Vision. “Telomere instability is a well-known hallmark of cancer. With TeloSizer®, we can accurately visualize and measure telomeres length.”

Christophe Lachaud, Group Leader at CRCM, commented: “We are very excited to utilize Genomic Vision’s TeloSizer® application to develop highly accurate companion tests that will benefit patients. TeloSizer® offers greater accuracy and more information compared to other telomere measurement methods.”

Vincent Geli, Deputy Director of CRCM expert in telomeres added: “TeloSizer® will provide new information on individual telomere length and their distribution.”

New tests will be developed as part of a four-year core scientific program collaboration set up between Genomic Vision and the CRCM and will utilize Genomic Vision’s DNA combing technology and TeloSizer® application. The program will employ scientific teams across the institute and will examine telomere length heterogeneity across different samples to uncover novel leukemia-specific telomere characteristics. Actionable insights from the project will be used for the development of personalize medicine approaches based on telomere morphology.

This project is part of the CRCM/IPC project supported by the OPALE Carnot Institute, a preferred partner to the healthcare Industry for research and development of innovative solutions aimed at diagnostic, treatment and follow-up of patients with leukemia, the blood cancer with the highest mortality rate, but also the leading cancer in children.

About Genomic Vision

GENOMIC VISION is a biotechnology company developing products and services dedicated to the analysis (structural and functional) of genome modifications as well as to the quality and safety control of these modifications, in particular in genome editing technologies and biomanufacturing processes. Genomic Vision proprietary tools, based on DNA combing technology and artificial intelligence, provide robust quantitative measurements needed for high confidence characterization of DNA alteration in the genome. These tools are also used for monitoring DNA replication in cancerous cell, for early cancer detection and the diagnosis of genetic diseases. Genomic Vision, based near Paris in Bagneux, is a public listed company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907).

For further information, please visit www.genomicvision.com.

About CRCM

The CRCM is affiliated with Inserm (UMR1068), the CNRS (UMR7258), the Aix-Marseille University (UM105) and the Institut Paoli-Calmettes (IPC). As a pioneer in the fight against cancer, the Marseille Cancer Research Center has been making every effort for 50 years to obtain a better understanding of the major biological mechanisms that are responsible for the disease and to translate them into medical innovations. By maintaining its efforts to characterize dysfunctions of the cancerous cell and immune system, the CRCM works alongside the IPC in a sustainable approach to improving patient care and quality of life, through the identification of new treatments.

For further information, please visit https://www.crcm-marseille.fr/en/the-crcm-celebrates-its-50th-anniversary/.

Member of the CAC® Mid & Small and CAC® All-Tradable indices

FORWARD LOOKING STATEMENT

This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the “Risk Factors” section of the universal registration document filed with the AMF on April 14, 2022 under reference number R.22-0293, as updated by the amendment filed with the AMF on May 20, 2022, under number D.22-0293-A01, available on the web site of Genomic Vision (www.genomicvision.com) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.
Contacts
Genomic VisionAaron Bensimon
CEO
Phone: +33 1 49 08 07 51
Email: investisseurs@genomicvision.com

Consilium Strategic CommunicationsInternational Investor Relations
& Strategic Communications
Tel: +44 (0) 20 3709 5700
GenomicVision@consilium-comms.com

Ulysse CommunicationMedia Relations
Bruno Arabian
Tél. : +33 1 42 68 29 70
barabian@ulysse-communication.com

NewCap
Investor relations
Phone: +33 1 44 71 94 94
Email: gv@newcap.eu